pandem
hardli
hit
world
extrem
import
signific
vitro
observ
guid
quick
set
clinic
trial
studi
evid
activ
clinic
achiev
hydroxychloroquin
concentr
maxim
administ
infect
vero
cell
strongli
suggest
combin
prophylact
therapeut
use
hydroxychloroquin
may
effect
limit
viral
replic
patient
th
march
directorgener
character
pandem
th
march
total
case
confirm
account
death
date
clinic
manag
subject
almost
exclus
consist
support
therapi
particular
ventilatori
support
sever
case
sever
drug
alreadi
clinic
trial
current
use
order
limit
inflammatori
respons
hamper
replic
regard
latter
drug
current
avail
consequ
need
repurpos
drug
use
set
chloroquin
cq
hydroxychloroquin
hcq
sever
studi
alreadi
demonstr
vitro
efficaci
cq
hcq
evidenc
latter
higher
activ
importantli
recent
studi
also
model
main
pharmacokinet
featur
hcq
tri
infer
lung
concentr
differ
dose
regimen
therefor
import
use
data
order
set
possibl
scenario
relat
real
clinic
use
drug
studi
test
hcq
italian
clinic
isol
use
differ
protocol
drug
administr
correspond
possibl
prophylact
therapeut
prophylactictherapeut
use
patient
singl
hcq
concentr
easili
reachabl
lung
character
high
activ
use
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
method
cell
viru
antivir
vero
vero
clone
atcc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
nonessenti
amino
acid
neaa
penicillinstreptomycin
ps
hepe
buffer
vv
fetal
bovin
serum
fb
clinic
isol
gisaid
access
id
isol
propag
vero
cell
viral
titer
determin
tissu
cultur
infect
dose
plaqu
assay
confirm
obtain
titer
infect
experi
perform
biosafeti
laboratori
microbiolog
virolog
vitasalut
san
raffael
univers
milan
itali
bafilomycin
bfla
obtain
merck
hydroxychloroquin
hcq
obtain
sigmaaldrich
viru
isol
aliquot
ml
transport
medium
nasopharyng
swab
copan
kit
univers
viral
transport
medium
copan
mildli
symptomat
infect
patient
mix
equal
volum
dmem
without
fb
supplement
doubl
concentr
ps
amphotericin
b
mixtur
ad
confluent
vero
cell
monolay
seed
cm
tissu
cultur
flask
h
adsorpt
ml
dmem
supplement
fb
amphotericin
b
ad
twentyfour
hour
postinfect
hpi
anoth
ml
dmem
supplement
fb
amphotericin
b
ad
live
imag
acquir
olympu
invert
phasecontrast
microscopi
daili
evid
cytopath
effect
cpe
aliquot
collect
viral
rna
extract
inhous
onestep
realtim
rtpcr
assay
five
day
postinfect
dpi
cell
supernat
collect
aliquot
store
secondari
viru
stock
vero
cell
seed
cm
tissu
cultur
flask
infect
ml
store
aliquot
infect
cell
supernat
collect
hpi
store
tertiari
viru
stock
vero
cell
seed
cm
tissu
cultur
flask
infect
ml
store
aliquot
prepar
describ
viru
titrat
viru
stock
titrat
use
plaqu
reduct
assay
pra
pfuml
endpoint
dilut
assay
eda
pra
confluent
monolay
vero
cell
infect
viru
stock
h
adsorpt
cellfre
viru
remov
cell
incub
h
dmem
contain
fb
agaros
cell
fix
stain
viral
plaqu
count
eda
vero
cell
cellsml
seed
well
plate
infect
base
dilut
viru
stock
h
adsorpt
cellfre
viru
remov
complet
medium
ad
cell
h
cell
observ
evalu
cpe
calcul
accord
reedmuench
method
viral
rna
mini
kit
follow
manufactur
instruct
revers
transcript
subsequ
amplif
perform
use
random
hexam
primer
amplicon
sequenc
illumina
miseq
ng
platform
illumina
san
diego
ca
usa
amplicon
purif
quantif
perform
agencourt
ampur
xp
beckman
coulter
villepint
franc
qubit
dsdna
assay
kit
thermofish
scientif
waltham
usa
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respect
librari
prepar
perform
use
nextera
xt
dna
librari
prep
kit
illumina
san
diego
ca
usa
librari
gener
dilut
sequenc
miseq
reagent
kit
illumina
san
diego
ca
usa
miseq
platform
qualiti
raw
sequenc
obtain
miseq
run
first
check
use
fastqc
v
babraham
bioinformat
read
align
refer
sequenc
gisaid
access
id
use
bwamem
rescu
use
samtool
alignmentmap
v
bamtofastq
final
contig
gener
use
spade
v
vero
cell
cellsml
seed
well
plate
treat
hcq
differ
stage
viru
infect
fulltim
treatment
cell
pretreat
drug
h
prior
viru
infect
follow
viru
adsorpt
h
presenc
molecul
cell
wash
pb
cultur
moleculecontain
medium
end
experi
preadsorpt
treatment
agent
ad
cell
h
viru
infect
maintain
viru
adsorpt
mixtur
replac
fresh
medium
without
molecul
till
end
experi
postadsorpt
assay
drugcontain
medium
ad
cell
viru
adsorpt
maintain
end
experi
cell
wash
pb
cultur
moleculecontain
medium
end
experi
bfla
nm
test
control
inhibit
viral
infect
phagolysosom
level
preadsorpt
treatment
alon
combin
preadsorpt
hcq
treatment
uninfect
cell
includ
experiment
set
exclud
possibl
drugtox
cpe
experiment
group
cell
infect
pfuml
absorpt
perform
live
imag
acquir
olympu
invert
phasecontrast
microscopi
cell
supernat
collect
realtim
pcr
rt
pcr
analysi
hpi
condit
test
quadrupl
viral
rna
extract
realtim
rtpcr
viral
rna
purifi
ml
cell
cultur
supernat
use
qiaamp
viral
rna
mini
kit
qiagen
follow
manufactur
instruct
subsequ
purifi
rna
use
perform
synthesi
firststrand
cdna
use
firststrand
synthesi
system
rtpcr
thermo
fisher
scientif
follow
manufactur
instruct
realtim
pcr
use
green
dyebas
pcr
amplif
detect
method
perform
order
detect
cdna
use
green
pcr
master
mix
thermo
fisher
scientif
forward
primer
tta
caa
aca
ttg
gcc
gca
aa
revers
primer
gcg
cga
cat
tcc
gaa
gaa
follow
pcr
condit
min
cycl
sec
anneal
sec
elong
sec
follow
final
elong
min
rtpcr
perform
use
abipr
fast
realtim
instrument
appli
biosystem
use
opticalgrad
plate
sampl
run
duplic
total
volum
statist
analysi
cpe
observ
differ
experiment
set
use
hcq
bfla
alon
combin
normal
correspond
viru
infect
control
rtpcr
result
analyz
calcul
delta
ct
differ
ct
valu
obtain
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
experiment
set
infect
control
twoway
anova
tukey
multipl
comparison
test
perform
evalu
ct
differ
graphpad
prism
viru
isol
sequenc
viru
isol
achiev
less
hour
hpi
cytopath
effect
cpe
alreadi
evid
vero
cell
ng
analysi
perform
illumina
miseq
obtain
whole
genom
sequenc
cultur
isol
gisaid
access
id
two
molecul
test
use
differ
experiment
protocol
viru
adsorpt
perform
cpe
assess
hpi
fig
viru
infect
posit
control
show
mark
effect
cell
morpholog
well
adsorpt
condit
hcq
effect
fulltim
treatment
adsorpt
temperatur
postadsorpt
treatment
viru
ad
cell
h
molecul
show
degre
protect
cpe
preadsorpt
treatment
adsorpt
temperatur
well
postadsorpt
treatment
adsorpt
bfla
test
control
inhibit
viral
infect
phagolysosom
level
preadsorpt
treatment
show
full
cpe
protect
viru
adsorpt
partial
protect
observ
viru
ad
cell
fig
drugrel
cytotox
effect
observ
uninfect
cell
experiment
set
data
shown
cell
supernat
differ
experiment
set
collect
analyz
rtpcr
result
confirm
cpe
data
analysi
fig
detail
signific
statist
differ
delta
ct
observ
hcq
fulltim
treatment
compar
infect
control
p
p
viru
adsorpt
hcq
postadsorpt
treatment
effect
p
viru
ad
cell
interestingli
bfla
addit
hcq
preadsorpt
treatment
result
signific
statist
differ
delta
ct
compar
infect
control
viru
adsorpt
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
lack
drug
extrem
import
evalu
clinic
potenti
drugrepurpos
order
face
current
pandem
hcq
gain
attent
scientif
medic
commun
base
previou
vitro
data
similar
virus
sar
mer
preliminari
report
discuss
possibl
clinic
effect
atyp
context
onfield
medicin
often
anticip
experiment
laboratori
preclin
urgent
need
prompt
experi
address
specif
clinic
question
exampl
clear
best
administr
regimen
maximis
possibl
hcq
antivir
effect
patient
regard
recent
studi
evalu
direct
effect
vitro
importantli
model
bioavail
lung
level
could
maxim
exert
antivir
activ
base
dose
regimen
mg
given
twice
daili
day
follow
mg
twice
daili
day
also
suggest
use
drug
concentr
use
clinicallyori
phenotyp
laboratori
assay
basi
evalu
hcq
antivir
activ
administ
preadsorpt
postadsorpt
fulltim
viru
adsorpt
order
simul
possibl
prophylact
therapeut
prophylactictherapeut
clinic
use
moreov
focus
attent
singl
concentr
um
easili
achiev
well
toler
endow
strong
antivir
activ
moreov
order
specul
possibl
mechan
action
also
evalu
hcq
activ
perform
viru
adsorpt
fact
viru
enter
cell
physiolog
context
convers
viru
dock
cell
receptor
internalis
much
limit
prophylact
set
preadsorpt
hcq
interfer
effect
viral
replic
cycl
neither
evidenc
cpe
rtpcr
analysi
limit
antivir
activ
also
observ
therapeut
set
postadsorpt
interestingli
higher
hcq
antivir
activ
observ
suggest
predomin
interfer
endosom
level
overal
importantli
result
suggest
limit
activ
hcq
administ
prophylact
therapeut
contrari
signific
antivir
activ
observ
prophylactictherapeut
fulltim
experiment
set
evidenc
cpe
rtpcr
analys
observ
allow
specul
need
combin
prophylact
therapeut
clinic
use
hcq
order
maximis
antivir
effect
atyp
scenario
ongo
pandem
preclin
medic
research
focus
simpl
fast
observ
potenti
use
prompt
set
clinic
trial
exampl
observ
could
easili
translat
clinic
studi
extrem
highrisk
categori
health
care
worker
base
prophylact
administr
hcq
follow
therapeut
use
case
posit
time
crucial
pandem
correct
clinic
repurpos
hcq
could
realli
invalu
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
median
valu
experiment
replic
test
one
duplic
rtpcr
ic
rang
report
error
bar
p
p
p
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
